Results 201 to 210 of about 413,185 (307)

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Adjuvant Autologous Platelet-Rich Plasma Gel for Decreasing Blood Loss in Posterior Placenta Previa: A Case Series and Literature Review. [PDF]

open access: yesCase Rep Obstet Gynecol
Duangkum C   +5 more
europepmc   +1 more source

Advanced therapy medicinal products (ATMPs) – An analysis of the global regulatory status

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Background A rapid progress in the development of advanced therapy medicinal products (ATMPs) has taken place over the past decades. The ATMPs hold great potential but face challenges in the clinical development and the regulatory process.
Allan Cramer   +4 more
wiley   +1 more source

Dried blood spot analysis in antidoping: Technical challenges, analytical advances, and future perspectives

open access: yesBulletin of the Korean Chemical Society, EarlyView.
Dried blood spot (DBS) analysis enables minimally invasive blood collection with strong analyte stability and simplified logistics, supporting anti‐doping applications beyond traditional matrices. Recent advances address hematocrit, volume variability, and matrix effects while expanding coverage to steroid esters, World Anti‐Doping Agency‐listed ...
Jihyun Yoon   +4 more
wiley   +1 more source

Neuronal differentiation and tissue engineering strategies for central neurous system injury repair

open access: yesBMEMat, EarlyView.
This review outlines tissue engineering advances for central nervous system (CNS) injury treatment, focusing on three core components: seed cells, inductive factors, and scaffold materials, with evaluation of their respective strengths and limitations. Tissue engineering for CNS injury repair.
Zhuqing Xia   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy